Technology Appraisal Guidance No. 349
Source: National Institute for Health and Care Excellence
1.1 Dexamethasone intravitreal implant is recommended as an option for treating diabetic macular oedema only if:
- the implant is to be used in an eye with an intraocular (pseudophakic) lens and
- the diabetic macular oedema does not respond to non-corticosteroid treatment, or such treatment is unsuitable.
1.2 People whose treatment with dexamethasone intravitreal implant was started within the NHS before this guidance was published, but is not recommended for them by NICE in this guidance, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://www.nice.org.uk/Guidance/TA349
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: email@example.com
Dexamethasone intravitreal implant for treating diabetic macular oedema
Issue Date: July 2015